Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A double-blind, randomized, placebo-controlled trial of misoprostol and routine uterotonics for the prevention of postpartum hemorrhage
International Journal of Gynecology and Obstetrics, Volume 112, No. 2, Year 2011
Notification
URL copied to clipboard!
Description
Objective: To assess the effects of 400-μg sublingual misoprostol plus routine uterotonics on postpartum hemorrhage. Methods: A double-blind, placebo-controlled, randomized study was performed. After delivery of the child, eligible women received routine uterotonics and were randomly allocated to receive 400-μg misoprostol or placebo sublingually. The primary outcome measure was blood loss of at least 500 mL within 1 hour of taking the trial tablets. Results: In total, 672 women received misoprostol and 673 received placebo. The baseline data were similar for both groups. Misoprostol plus routine uterotonics reduced postpartum blood loss, but the effect was not significant for blood loss of at least 500 mL (relative risk [RR] 0.96; 95% confidence interval [CI], 0.63-1.45) or blood loss of at least 1000 mL (RR 0.50; 95% CI, 0.15-1.66). Misoprostol also reduced the need for non-routine oxytocin, manual removal of the placenta, and hysterectomy, but these differences were not significant either. Misoprostol was associated with pyrexia and moderate/severe shivering. There was no death in either group. Conclusion: Misoprostol plus routine uterotonics resulted in modest reductions of blood loss in the third stage of labor, but the effects did not reach statistical significance. Larger studies are recommended. © 2010 International Federation of Gynecology and Obstetrics.
Authors & Co-Authors
Fawole, Adeniran Olubukola
Nigeria, Ibadan
University College Hospital, Ibadan
Sotiloye, Oladapo
Nigeria
Federal Medical Centre Nigeria
Hunyinbo, Kehinde Isaac
Nigeria
Federal Medical Centre Nigeria
Umezulike, Augustine C.
Nigeria, Abuja
National Hospital, Abuja
Okunlola, Michael Abiola
Nigeria, Ibadan
University College Hospital, Ibadan
Adekanle, D. A.
Nigeria, Osogbo
Lautech Teaching Hospital
Osamor, Jonathan
Nigeria, Ibadan
Adeoyo Maternity Teaching Hospital
Adeyanju, Olusoji A.
Nigeria, Ibadan
Adeoyo Maternity Teaching Hospital
Olowookere, Olufemi Oluwole
Nigeria, Ibadan
University College Hospital, Ibadan
Adekunle, Adeyemi O.
Nigeria, Ibadan
University College Hospital, Ibadan
Singata-Madliki, Mandisa
South Africa, Johannesburg
University of the Witwatersrand
Mangesi, Lindeka
South Africa, Johannesburg
University of the Witwatersrand
Hofmeyr, George Justus
South Africa, Johannesburg
University of the Witwatersrand
Statistics
Citations: 27
Authors: 13
Affiliations: 6
Identifiers
Doi:
10.1016/j.ijgo.2010.08.023
ISSN:
00207292
Research Areas
Disability
Maternal And Child Health
Participants Gender
Female